

Chronic Myelogenous Leukemia (CML) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: __1st Line __2nd Line __3rd Line __3rd Line+ ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (select all that apply)

CML Phase: __ Chronic Phase __ Accelerated Phase __ Lymphoid Blast Phase __ Myeloid Blast Phase __ Not Reported

Imatinib resistant or intolerant: __ Yes __ No Philadelphia chromosome: __ Positive __ Negative

T315I: __ Positive __ Negative Mutation: ___V299L ___T315I

First Line of Therapy (1st Line) | Low Risk Disease

Imatinib (Gleevec)

First Line of Therapy (1st Line) | Intermediate or High Risk Disease*

Dasatinib (Sprycel)

Imatinib (Gleevec)

Nilotinib (Tasigna)

Second Line of Therapy (2nd Line) | Following Treatment Failure, Suboptimal Response†, or Intolerance to 1st Line

Bosutinib (Bosulif)

Dasatinib (Sprycel)

Nilotinib (Tasigna)

Ponatinib (Iclusig)‡

Third Line of Therapy (3rd Line)

Ponatinib (Iclusig)

*For patients with intermediate or high risk disease based on Sokal or Hasford score:

- Sokal: Intermediate Risk=0.8-1.2; High Risk>1.2
- Hasford: Intermediate Risk=781-1480; High Risk>1480

†Defined as lack of complete hematologic response or BCR-ABL1 transcripts > 10% (IS) or lack of partial cytogenetic response on bone marrow cytogenetics.

‡Pathway option for second line therapy only after failure, suboptimal response, or intolerance of a second generation TKI has been used in the first line setting, or T315I mutation has been identified.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

